P604 Biologics with or without a combination with 5-ASA in ulcerative colitis: frequency of usage and effect on the course of disease in the Swiss IBD-Cohort study
R. Roth*1, P. Schreiner1, J-B. Rossel2, B. Misselwitz3, M. Scharl1, G. Rogler1, L. Biedermann1
1University Hospital Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland, 2University of Lausanne, Institute of Social and Preventive Medicine, Lausanne, Switzerland, 3University Hospital Bern, Department of Visceral Surgery and Medicine, Bern, Switzerland
5-ASA remains the mainstay of therapy in mild-to-moderate ulcerative colitis (UC) enabling achievement of remission in between 50–75% of all patients. Combination of immunosuppressives (IS) has been found to be associated with a better outcome when compared with monotherapy. However, concerning 5-ASA combination with biologics, clinical practice is highly variable and the evidence on potential benefit is scarce. We aimed to evaluate the course of UC in patients being treated with a combination of 5-ASA and biologics vs. biologics alone.
We analysed the prospectively collected clinical data from all UC patients currently receiving biologic treatment and participating in the nation-wide Swiss IBD cohort study (SIBDCS) with vs. without 5-ASA co-treatment.
At last clinical follow-up visit amongst the 366 identified UC patients with currently ongoing biologic treatment, 170 received 5-ASA co-treatment. Regarding key baseline characteristics, including sex, duration of disease and age at UC diagnosis, there were no differences between patients with vs. without 5-ASA. More patients with 5-ASA co-treatment were under concomitant therapy with IS and/or steroids. Moreover, disease activity in the 5-ASA combination group was significantly higher. No differences across groups were identified considering most recent, maximal and average levels of faecal calprotectin and leucocyte count, CRP and haemoglobin from blood samples. The occurrence of complications, for example, cancer, dysplasia, anaemia, osteoporosis, thromboembolism or extraintestinal manifestations (EIM) was similar. However, combination lead to less intestinal surgery.
|Population characteristics||Biologics only (%)||Biologics+5-ASA (%)||Significant|
|Number||196 (53.6)||170 (46.4)||No|
|Male||105 (53.6)||90 (52.9)||No|
|Female||91 (46.4)||80 (47.1)||No|
|MTWAI Median; IQR||5; 2–8||6; 4–10|
|Immunomodulators||33 (16.8)||43 (25.3)|
|Steroid||39 (19.9)||55 (32.4)|
|Events||Biologics only (%)||Biologics+5-ASA (%)||Significant|
|Complications||114 (58.2)||107 (62.9)||No|
|EIM||105 (53.6)||93 (54.7)||No|
|Intestinal Surgery||16 (8.2)||5 (2.9)|
In our cohort, we found that UC patients under biologic therapy receiving 5-ASA co-treatment had a similar risk of complications or EIM while having a lower risk of colonic surgery. This being despite the fact that 5-ASA co-treated patients appear to reflect a subgroup of UC patients with a more severe course of disease as suggested by disease activity and co-treatment with IS and steroids. As no randomised prospective studies investigating this issue can be expected, further long-term observations in cohort studies and registries are mandatory to investigate the place of concomitant 5-ASA in UC patients receiving ‘advanced’ treatments.